Navigation Links
Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
Date:5/13/2008

40 women in this study. The combination of mammography and ultrasound screening prompted an unnecessary biopsy for one in 10 women, or four times more women having an unnecessary biopsy.

According to the study's principal investigator, Wendie Berg, M.D., Ph.D., a radiologist specializing in breast imaging with American Radiology Services at Johns Hopkins Green Spring, Lutherville, Md., "The study results confirm that screening ultrasound in combination with mammography detects more cancers than mammography alone in women at increased risk for breast cancer. However, this benefit comes with the added risk of a false positive result. If we are going to offer screening ultrasound, we need to inform women of the substantial risk of receiving an unnecessary biopsy."

The study's statistician, Jeffrey Blume, Ph.D., associate professor and deputy director of the ACRIN Biostatistics and Data Management Center at Brown University in Providence, R.I., emphasized the reliability of these results: "Rigorous, well controlled trials like this one - where participants uniformly undergo both screening exams in a randomized order and investigators interpreting one exam are masked to the results of the other - yield the highest level of medical evidence. A study as large as this one could not have been completed without the ongoing support and cooperation of NCI and Avon."

The American Cancer Society recently recommended that certain women at very high risk for breast cancer be screened with magnetic resonance imaging (MRI) in addition to mammography, and these results do not change that recommendation. Women who do have screening MRI do not need screening ultrasound. Women who are at increased risk, who are currently undergoing mammographic screening and are not recommended for MRI, or for whom it is not available or not tolerated, may wish to consider adding screening ultrasound. Women should talk with their doctor about their breast cancer risk profile a
'/>"/>

SOURCE American College of Radiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
7. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2US Oncology Reports Second Quarter Operating Results 53858 1US Oncology Reports Second Quarter Operating Results 53858 2US Oncology Reports Second Quarter Operating Results 53858 3US Oncology Reports Second Quarter Operating Results 53858 4US Oncology Reports Second Quarter Operating Results 53858 5US Oncology Reports Second Quarter Operating Results 53858 6US Oncology Reports Second Quarter Operating Results 53858 7US Oncology Reports Second Quarter Operating Results 53858 8US Oncology Reports Second Quarter Operating Results 53858 9US Oncology Reports Second Quarter Operating Results 53858 10US Oncology Reports Second Quarter Operating Results 53858 11US Oncology Reports Second Quarter Operating Results 53858 12US Oncology Reports Second Quarter Operating Results 53858 13US Oncology Reports Second Quarter Operating Results 53858 14US Oncology Reports Second Quarter Operating Results 53858 15US Oncology Reports Second Quarter Operating Results 53858 16US Oncology Reports Second Quarter Operating Results 53858 17US Oncology Reports Second Quarter Operating Results 53858 18US Oncology Reports Second Quarter Operating Results 53858 19US Oncology Reports Second Quarter Operating Results 53858 20US Oncology Reports Second Quarter Operating Results 53858 21US Oncology Reports Second Quarter Operating Results 53858 22US Oncology Reports Second Quarter Operating Results 53858 23US Oncology Reports Second Quarter Operating Results 53858 24US Oncology Reports Second Quarter Operating Results 53858 25Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 1Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 2Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 3BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 1BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 2BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 3
...o, a division of Merck KGaA, Darmstadt, Germany, t... develop and commercialize Ambrx,s ARX424 preclini...e sclerosis. ARX424 was created by Ambrx through ...ation technology, ReCODE(TM). , , This second col...vious agreement announced in 2007 to develop ARX20...
...ceuticals, Inc. (Nasdaq: MAPP ) announced today ...nit Dose Budesonide (UDB) for the potential,treatm...d that the clinical,trial did not meet its co-prim...es from baseline in nighttime and daytime composit..., when compared with placebo. Median,nebulization...
Other Medicine Technology:Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 2Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 3MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...CFS) has been associated with altered amounts of s...oencephalograph (EEG) activity and impaired sleep... journal SLEEP finds that CFS is also associated w...Roseanna Armitage, PhD, and colleagues at the Univ...
... not pose a risk of cancer; a Danish study conduct... has shown. Danish medical records were a... cancer, or brain cancer among the utility workers...bstantial evidence linking exposure to electro mag...
... have died in a hospital here in the month of Apri...ed from his post for not informing the state gove...s, however, put the number of infant deaths at the...sts conducted at the microbiology department of th...
...eed lift one out of depression. But its potential ...ognized . Now the U.S. Food and Drug Admin...tidepressant medications update the existing black...ring initial treatment, generally the first one to...
...Dakota is now infusing roasted sunflower seeds w...energy drinks , to provide players and other peopl... The product, which has been under developmen...e, lysine and ginseng are added. The 3.5-ounc...
...rchers, diabetes is fast becoming a common reason ...he Reproductive Medicine Research Group at Queen's... semen samples of 57 men who were diagnosed with D...such samples it was seen that diabetes brought abo...
Other Medicine News:Health News:Government Expels Superintendent for Not Informing Newborn Deaths 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:Fertility Rates Felled By Diabetes 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: